Navigation Links
Yondelis(R) Sales Expanded by 70 Percent
Date:10/28/2010

MADRID, Oct. 28 /PRNewswire/ -- Group revenues totaled 120 million euro (approximately 167 million USD*) in the first nine months of 2010, i.e. an increase of 26.1 percent with respect to the same period last year (95.19 million euro or approximately 132.6 million USD).

Net sales in the Biopharmaceutical business amounted to 56.9 million euro or approximately 79.3 million USD (35.8 million euro or approximately 49.9 million USD in the first nine months of 2009), of which 51.8 million (approximately 72.1 million USD) correspond to Yondelis sales (30.4 million euro or approximately 42.3 million USD in 9M09). Genomica's sales totaled 5.1 million euro (approximately 7.1 million USD).

The Consumer chemicals division reported sales of 62.2 million euro or approximately 86.6 million USD (58.6 million euro or approximately 81.6 million USD in 9M09). This division accounted for 51.8 percent of total group revenues in the first nine months of 2010 (61.5 percent in 9M09).

The Group maintained positive EBITDA of 2.7 million euro (approximately 3.8 million USD) in 9M10, driven by steadily rising sales since the beginning of the year.

Net income attributable to the parent company improved 63 percent with respect to September 2009.

About Zeltia

Zeltia S.A. is a world-leading biopharmaceutical company specialized in the development of marine-based drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Noscira, a biotech firm focused on discovering and developing new drugs against Alzheimer's disease and other neurodegenerative diseases of the central nervous system; Genomica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two profitable companies that are leaders in their respective market segments.

For more information, Zeltia +34 91 444 4500

This note is also available at Zeltia's web site: www.zeltia.com

* All original figures are in Euros; dollar figures are estimated using the exchange rate: 1.3928.


'/>"/>
SOURCE Zeltia
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abaxis Reports Financial Performance with Record Sales for the Second Quarter of Fiscal 2011
2. Decision Resources Forecast of Global Tanezumab Sales Slashed Following FDA Halt of Phase III Studies
3. Sinovac Announces Preliminary Unaudited Third Quarter 2010 Sales Range and Revises Full Year 2010 Sales Expectations
4. Assured Pharmacy Reports Same Store Sales for the Month of September 2010
5. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter and Nine-Months Ended September 30, 2010 and Declares Quarterly Dividend
6. Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010
7. Reportlinker Adds Sales Force Effectiveness in Pharmaceuticals - Cost Pressures Increase Pharmaceutical Companies Adoption of New Sales Models and Technologies
8. Gerresheimer Reports Strong Earnings and Sales Growth
9. Nonin Medical, Inc. Announces Capnography Division Name Change; Expands Swedish Manufacturing Facility to Become Full-Franchise European Sales, Distribution and Service Center
10. Health Strategies Group Introduces New One-Stop Suite of Intelligence Services for Optimizing Marketing and Sales Resources in the Institutional Channel
11. Universal SmartComp Ranks No. 503 Overall and No. 35 in the Health Sector on the 2010 Inc. 5000 with Three-Year Sales Growth of 600%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Research ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production Complexities ... to their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming ... provides an in-depth assessment of the current trends in ...
(Date:4/20/2017)... April 20, 2017   ZappRx, Inc ., a digital ... prescribing process, today announced it closed $25 million in Series ... capital firm based in Seattle that ... Partners . The Series B round included participation from ... 2014, and GV (formerly Google Ventures). As part ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... Datos Health , developer of a ... Med-e-Mass , the largest Electronic Medical Records (EMR) provider in South Africa. By ... to a patient’s remote health progress, empowering the patient to take direct responsibility for ...
(Date:4/26/2017)... ... ... RawTrition now brings you BioEnergy which is a powder capsule whole food ... RawTrition is taking nutrients to the next level! The superfoods in RawTrition's BioEnergy ... (unlike the synthetically made options that are on the market). , Founder of RawTrition, ...
(Date:4/25/2017)... ... 2017 , ... Bellus Medical, a leader in medical aesthetics, ... class of photodynamic cosmetics (PDC). , Allumera® is the first PDC cream specifically ... aging, and minimize the appearance of pores – all with minimal downtime and ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... and HR decision-makers are preparing for how his administration could impact the employee ... insight into what changes are most likely to make it through Congress. His ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... rely on contracted partners to help with process innovation in drug formulation and ... formulation experience along with state-of-the-art analytical equipment in support of their development and ...
Breaking Medicine News(10 mins):